SIX Trading Key Figures: April 2021 Date
03/05/2021
In April 2021 trading turnover on the Swiss Stock Exchange reached CHF 109.8 billion, 20.6% less than in the previous month, while the number of transactions decreased by 19.4% to a total of 5,148,483. Since the beginning of 2021, trading turnover reached CHF 486.8 billion with a total of 24,313,936 transactions. The SMI® fell by 0.2% and reached 11,022.3 points at the end of the month.
Trading turnover of CHF 109.8 billion (-20.6% month-on-month)
Number of trades 5,148,483 (-19.4% month-on-month)
SMI® index at 11,022.3 points at the end of April (-0.2% month-on-month)
The highest turnover on a single trading day was recorded on 16 April, which saw securities worth a total volume of CHF 6.8 billion changing hands. The highest number of trades was recorded on 6 April, with 305,207. The stock that generated the highest turnover during the reporting month was NESTLE N with CHF 11.0 billion; CS GROUP N was the most traded
Switzerland
Swiss
Swiss-stock-exchange
சுவிட்சர்லாந்து
சுவிஸ்
சுவிஸ்-ஸ்டாக்-பரிமாற்றம்
Regulatory News:
Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced positive results from a phase-III study in China (PA-CL-CHINA-01), evaluating the efficacy of Velphoro® (PA21) compared to sevelamer carbonate in lowering and maintaining serum phosphorus in adult Chinese patients with chronic kidney disease (CKD) on dialysis after 12 weeks of treatment. The study met its primary endpoint demonstrating non-inferiority versus sevelamer carbonate in the change from baseline in serum phosphorus levels at week 12.
Dr. Klaus Henning Jensen, Chief Medical Officer of Vifor Pharma Group commented, “We are delighted by the positive results from the PA-CL-CHINA-01 study, which confirm previous data generated in the US and Europe, and reinforce the potential of Velphoro® as an important new treatment option for dialysis patients with hyperphosphatemia in China where there is a high prevalence of CKD1. This is another important step in our geographic expansion and will furt
China
Switzerland
Chinese
Swiss
Vifor-pharma
Klaus-henning-jensen
Swiss-stock-exchange
Vifor-pharma-group
National-medical-products-administration
Swiss-exchange
Intj-environ-res-public-health
Fresenius-medical-care